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Int J Geriatr Psychiatry. 2018;1–7.Introduction: To objectively quantify patients' physical activity and analyze the rela-
tionships between physical activity levels, psychopathology, and sedative medication
in acute hospital dementia care.
Materials and Methods: In this cross‐sectional study, we assessed the patients'
physical activity based on data collection by hybrid motion sensors attached on their
lower back. Daily doses of antipsychotics have been converted to olanzapine‐
equivalents and daily benzodiazepine medication is reported as diazepam‐
equivalents. We assessed patients' neuropsychiatric symptoms with the Neuropsychi-
atric Inventory and the Cohen‐Mansfield Agitation Inventory.
Results: We analyzed motion sensor data from 64 patients (MMSE M = 18.6). On
average, patients were lying for 11.5 hours, sitting/standing sedentary for 10.3 hours,
sitting/standing active for 1.0 hours, and walking for 1.2 hours per day. The analysis
revealed no correlations between patients' physical activity and antipsychotic or ben-
zodiazepine medication. More severe neuropsychiatric symptoms were associated
with a decrease in the patients' physical activity (r = .32, P = .01). In particular, patients
with apathy symptoms were less physically active than patients without apathy
symptoms.
Discussion: The results reveal that most of the patients in acute dementia care had
very low levels of physical activity. Their physical inactivity may be due to the severity
of their neuropsychiatric symptoms, especially apathy. Antipsychotic and benzodiaze-
pine medication appeared to have less impact on patients' physical activity. Dementia
care should pay more attention to prevent physical inactivity in patients.
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Key points
• Patients in acute dementia care show an unexpected
low level of physical activity
• Psychopathological symptoms—especially apathy—are
related to the low level of physical inactivity, not the
dose of sedative medication
• Dementia care should pay more attention to prevent
physical inactivity in patients
2 FLEINER ET AL.1 | INTRODUCTION
Dementia is one of the biggest global health care challenges of our
time. In 2016, there were more than 47 million people suffering from
dementia, and this number will increase to more than 131 million by
2050.1 Alongside the cognitive impairment, neuropsychiatric signs
and symptoms (NPS) in dementia are a big challenge for clinical psy-
chiatry and lead to a high caregiver burden.2 During the course of the
disease, almost every patient suffers from NPS.3 The term NPS
covers psychological symptoms such as delusions, hallucinations,
depression, sleeplessness and anxiety, and behavioral symptoms
such as physical aggression, wandering, and restlessness.4 Periods
of exacerbated NPS often lead to hospital admission and early
institutionalization.5
Pharmacological and non‐pharmacological treatment of NPS is
one of the key challenges in dementia care. Non‐pharmacological
treatments are generally the first‐line treatments for NPS, eg, staff
training in NPS management strategies, recreational activities, music
therapy, or other forms of sensory stimulation.6 Recent reviews indi-
cate that physical exercise interventions have a positive impact on
NPS.7,8 The pharmacological treatments for NPS are antipsychotics,
anticonvulsants, antidepressants, anxiolytics, benzodiazepines, cholin-
esterase inhibitors, and NMDA modulators.9
There is growing evidence of a link between dementia patients'
physical activity level and NPS.10 Christofoletti et al11 found that
more sedentary patients exhibited more NPS, which raises the issue
of the impact of antipsychotic and benzodiazepine medication on
the physical activity levels of patients in acute dementia care.
We aimed to take advantage of the increasing use of technology
in geriatric psychiatry12 to quantify acute dementia patients' physical
activity objectively and analyze the relationship between patients'
physical activity levels, psychopathology, and sedative medication.2 | MATERIALS AND INSTRUMENTS
2.1 | Study design
We conducted a cross‐sectional investigation in the Department of
Geriatric Psychiatry of the LVR‐Hospital in Cologne as part of a ran-
domized clinical trial.13 This analysis includes the baseline measure-
ments of all patients before randomization. The Ethics Commission
of the German Sport University Cologne and the Ethics Commission
of the North‐Rhine Medical Chamber approved the study (reference
number: 2014216). German National Register of Clinical Trials:
DRKS00006740, date of registration: 28.10.2014).2.2 | Sample
The sample comprised patients from two closed dementia wards. The
inclusion criteria were (1) diagnosis of dementia according to ICD‐10‐
criteria,14 (2) ability to perform the timed up and Go test (TuG)15 with-
out assistance, and (3) written informed consent from the patient, if
the patient had a score of ≥20 in the Mini Mental Status Examination(MMSE)16 and was able to rephrase the aims and content of the study
in his own words; in patients with a MMSE <20, written consent from
the patient and written informed consent from his or her legal guard-
ian was required. The exclusion criteria were diagnosis of symptom-
atic, non‐vascular or non‐neurodegenerative dementia, diagnosis of
delirium, and no legal guardian. In total 87 patients were recruited
for the umbrella RCT. The baseline assessment results of this sample
have been included in this analysis.2.3 | Data acquisition
The assessment of the patients' physical activity was based on a
72‐hour period of data acquisition by a hybrid motion sensor
(uSense) fixed on the patients' lower back. Based on these record-
ings, we analyzed patients' physical activity over a 24‐hour period
from 00:00 and 24:00, using 1‐second time bins. The uSense wear-
able sensor and its software for signal processing and activity recog-
nition are an outcome of the FARSEEING EU project. The software
allows quantitative data analysis, and it has already been used in
patients with dementia,17 in older people residing in independent‐
living retirement homes,18 and in community‐dwelling older adults.19
The activity recognition software is able to identify four activity
states: lying; sedentary, either sitting or standing; active, either sit-
ting or standing; and walking. In addition, daily step counts were
analyzed. For this trial, we analyzed dementia patients' doses of anti-
psychotics and benzodiazepines for the 24‐hour period in which the
activity assessment was carried out. Dose of antipsychotics was con-
verted into the olanzapine‐equivalent dose per day.20 Dose of ben-
zodiazepine medication was converted into the diazepam‐
equivalent dose per day.21
We used MMSE,16 Demtect,22 and Clock Drawing test23 to assess
cognitive impairment. Information about cognitive reserve was also
captured.24 The Bayer Activities of Daily Living scale was used to esti-
mate patients' ability to perform everyday activities.25 The TuG15 and
the 10‐m gait speed test were used to measure patients' mobility.25
Neuropsychiatric symptoms were assessed using the Neuropsychiatric
Inventory (NPI)27 and the Cohen‐Mansfield Agitation Inventory
(CMAI)28 was used to rate the patients' agitation symptoms. All out-
come measurements were conducted by experienced assessors from
nursing and medical staff.
FLEINER ET AL. 32.4 | Statistical analysis
All statistical analyses were performed using SPSS Version 24.0.29
Outliers in the dependent variables (OPZ, DPZ, physical activity,
CMAI, NPI) were excluded by the 1.5‐fold inter‐quartile from the
upper or lower box plot quartile. We analyzed differences between
the two medication groups (use of antipsychotics and/or benzodiaze-
pines vs no medication) with Chi‐squared tests in the case of categor-
ical variables (sex, dementia diagnosis), Mann‐Whitney U‐test in the
case of ordinal variables (NPI, CMAI, Bayer Activities of Daily Living),
unpaired t‐tests in the case of normally distributed continuous vari-
ables (body mass index, MMSE, Demtect, clock‐drawing test, TUG,
10‐m gait speed, physical activity levels), and Mann‐Whitney U‐tests
in the case of nonparametric continuous variables. We used Pearson's
correlations to assess of the relationship between use of antipsy-
chotics and benzodiazepines and patient's physical activity.
Correlation ranges of .70 to .90 were regarded as high, ranges of
.50 to .70 as moderate, and ranges of .30 to .50 as low.30 A signifi-
cance level of α = .05 was used for all tests.3 | RESULTS
Eighty‐seven patients were recruited for this trial. Initially, 86 patients
accepted the uSense sensor attachment. One patient refused the sen-
sor attachment at the beginning. Five patients removed the device dur-
ing the 72‐hour recording period. In the raw data analysis, weTABLE 1 Patient characteristics (N = 64; female n = 30 [47%])
M
Age 81







Mini‐mental status examination 18.6
Demtect 4.2
Clock‐drawing test 5.0
Neuropsychiatric inventory (NPI) 19.2
Cohen‐Mansfield agitation inventory (CMAI) 49.1
Cognitive reserve capacity, years of education 11.9
Bayer‐activities of daily living 7.7
Timed up and go test [s] 14.4
10 meter gait speed [m/s] 0.8
Benzodiazepine dose (DED) [mg/day] 4.0




No benzodiazepines or antipsychotics
M = mean; SD = standard deviation; Min. = minimum; Max. = maximum; Range a
no symptoms); CMAI: 29‐203 points (29 meaning no symptoms); DED = Diazediscovered that four data sets were incomplete or missing. One patient
who moved with the help of a four‐wheeled walker was excluded from
the analysis of gait time and total steps per day because we were
unable to detect her steps accurately. Correction for outliers elimi-
nated n = 7 patients due to their physical activity and n = 6 patients
due to the applied sedative medication. No patient was excluded due
to the NPS. Out of the N = 87 recruited patients, n = 64 patients with
a synchronized 24‐hour sensor‐recording were included in the analysis.
The group's characteristics are presented in Table 1.
Most of the patients (53%) suffered from mixed type of dementia.
All patients completed the MMSE, and the mean MMSE score was
18.6 points. Not all patients performed the Demtect (N = 58) and
Clock drawing test (N = 57) because some of them had problems
understanding the instructions. Forty‐eight of the 64 patients received
antipsychotic medication, and 10 patients received benzodiazepine
medication. We did not find any differences regarding patient charac-
teristics, neuropsychiatric symptoms, and OPZ/DPZ between the
n = 64 included and the n = 10 patients, who refused or had incom-
plete data sets and the n = 13 outliers. The neuropsychiatric symp-
toms of the sample are shown in Table 2.
The most common symptoms in the final sample (N = 64) were
agitation and aggression (59%), depression and dysphoria (52%), and
irritability and lability (56%). Means for physical activity parameters,
based on the sensor data, are shown in Table 3.
Patients' daily number of steps ranged from 796 to 13 885, and
the mean number of steps per day was 6193 (SD = 3204). The mean
duration of physical inactivity (sum of daily hours of lying andSD Min. Max. N (%)
6.2 67 95 64






5.5 7 27 64
1.6 1 6 58
3.4 0 14 57
12.2 0 51 64
12.0 29 83 64
2.6 7 18 63
1.6 2.3 9.7 64
5.2 7.3 32.9 64
0.2 0.3 1.6 64
1.9 0.3 7.5 10 (16)





nd scaling of psychopathometric instruments: NPI: 0‐144 points (0 meaning
pam equivalent dose; OED = Olanzapine equivalent dose.
TABLE 2 Psychopathological symptoms in terms of the neuropsychiatric inventory (NPI) domains (N = 64)
NPI Domains n (%) M SD Min. Max.
Delusions 22 (34) 6.5 3.0 2 12
Hallucinations 10 (16) 7.1 4.0 2 12
Agitation/aggression 38 (59) 5.7 2.8 2 12
Depression/dysphoria 33 (52) 4.8 3.0 1 12
Anxiety 18 (28) 5.8 2.8 2 12
Elation/euphoria 3 (5) 4.7 3.1 2 8
Apathy/indifference 29 (45) 4.7 2.1 1 8
Disinhibition 10 (16) 4.9 3.0 3 12
Irritability/lability 36 (56) 5.1 2.4 2 12
Aberrant motor behavior 30 (47) 5.1 1.9 3 8
Sleep and night‐time behavior disorders 12 (19) 6.1 1.9 3 9
Appetite/eating changes 3 (5) 10.7 2.3 8 12
Patients symptoms; frequency*severity scores (0‐12; 0 indicates absent); M = mean; SD = standard deviation; Min. = minimum; Max. = minimum.
TABLE 3 Sensor‐based means for physical activity parameters (N = 64; N = 63 for “gait” and “steps” [see text for further explanation])
N M SD Min. Max.
Posture/activity
Lying, h/day (%) 64 11.5 (48) 2.1 (9) 6.5 (27) 16.0 (67)
Sedentary sitting/standing, h/day (%) 64 10.3 (43) 2.1 (9) 6.0 (25) 15.3 (64)
Active sitting/standing, h/day (%) 64 1.0 (4) 0.4 (2) 0.3 (1) 2.1 (9)
Gait, h/day (%) 63 1.2 (5) 0.6 (3) 0.2 (1) 2.6 (11)
Total steps per day 63 6193 3204 796 13 885
M = mean; SD = standard deviation; Min. = minimum; Max. = maximum.
4 FLEINER ET AL.sedentary sitting/standing) was 21 hours 50 minutes, representing
91% of the day (Figure 1). Duration of physical inactivity ranged from
19 hours 20 minutes to 23 hours 12 minutes per day.
Correlations between patients' physical activity and their doses of
antipsychotic and benzodiazepine medication are shown in Table 4.
The analysis revealed no correlations between physical activity
and dose of antipsychotics or benzodiazepines. Physical inactivity
was not correlated with diazepam‐equivalent dose (r = .09, P = .46)
or olanzapine‐equivalent dose (r = .20, P = .11). Compared with the
group of patients who only received antipsychotics (n = 39), the group
receiving both antipsychotic and benzodiazepine medication (n = 9)
spent more time lying down (z = −2.31, P = 0.02). Physical activity
was similar in the group of patients not taking either kind of medica-
tion (n = 15) and the nine patients receiving both, antipsychotics and
benzodiazepines, eg, for lying h/day (z = −1.73, P = 0.08) or steps
per day (z = −0.09, P = 0.95).
Total NPI score shows a moderate positively correlation to the
patients' physical inactivity (r = .32, P = .01). Psychopathological symp-
toms expressed as NPI score were negatively associated physical
activity. More severe psychopathological symptoms as rated with
the NPI are associated with less physical activity. There were n = 29
patients (45%) suffering from apathy symptoms, and the mean dura-
tion of physical inactivity in this subgroup was 22 hours
5 minutes/day (SD = 4). On average n = 35 patients (56%) without
apathy symptoms were active for 27 minutes more per day thanpatients with apathy symptoms (z = −2.12, P = 0.34). Total CMAI score
was not correlated with physical inactivity (r = −0.21, P = .11).4 | DISCUSSION
The aim of this study was to assess overall physical activity level in a
large cohort of patients in acute dementia care. We also investigated
the relationships between physical activity and psychopathological
symptoms and use of antipsychotic and benzodiazepine medication
in patients receiving acute dementia care.
The results revealed that most patients in acute dementia care
had very low levels of physical activity. The NPI showed a positive
correlation to the patients' physical inactivity, with more severe psy-
chopathological symptoms related to a lower amount of physical activ-
ity. Overall, patients' level of physical inactivity does not seem to be
associated with their dosage of antipsychotic or benzodiazepine med-
ication, but the small group of patients receiving both antipsychotics
and benzodiazepines (n = 9, 14%) were sedentary for a greater propor-
tion of the day than other patients. This might be due to receipt of
benzodiazepine medication in addition to antipsychotics. Alternatively,
more severe psychopathology may be responsible for the low level of
physical activity. Our results reveal that psychopathological symp-
toms, as measured by the NPI, play an important role in explaining
physical inactivity in most of our patients. In particular, we found a
FIGURE 1 Sensor‐derived physical activity
data [mean total hours/posture/day] (N = 64;
N = 63 for “gait” and “steps” [see text for
further explanation])
TABLE 4 Correlations between patients' physical activity and benzodiazepine medication (diazepam‐equivalent dose; DED) and antipsychotic
medication (olanzapine‐equivalent dose; OED)
n
Lying, h/day Sed, h/day Act, h/day n Gait, h/day Steps/day
r P r P r P r P r P
DED 10 0.25 0.50 −0.20 0.57 0.21 0.57 9 −0.32 0.40 −0.19 0.63
OED 48 −0.01 0.93 0.11 0.46 −0.19 0.19 47 −0.13 0.75 −0.16 0.70
Sed = sedentary sitting/standing; Act = active sitting/standing; steps = total steps per day; r = Pearson correlation coefficient; Note: Gait and steps/day: one
patient had to be excluded—see text for further explanation.
FLEINER ET AL. 5low correlation of the NPI score with the patients' physical inactivity
and that apathy symptoms, present in 29 patients (45%) patients, were
linked to lower physical activity; mean duration of physical activity in
patients showing apathy was 27 minutes per day less than in the 35
patients (55%) who did not show apathy.
Our patients were physically inactive for more than 90% of the
day, eg, some patients were inactive for more than 23 hours per
day. Similar low levels of physical activity and correlations to NPS in
dementia care have been reported by Christofoletti et al,11 and studies
in which wrist‐worn actigraphic devices were used to assess patients'
physical activity.31-33 Unlike wrist actigraphy, using hybrid motion sen-
sors attached to the lower back, as we did in this trial, allows to ana-
lyze mobility‐related physical activity rather than just upper limb
movement.
Using motion sensors allows patients' physical activity to be quan-
tified objectively. The sensor data indicate that our sample was seden-
tary and physically inactive for most of the day (Figure 1), eg, some
patients only get up from bed or stand up from a chair to go to the toi-
let or take meals. The use of objective measures of the patients' phys-
ical activity puts a focus on one of the major problems in dementia
care: patients' physical inactivity. In acute dementia care settings,
patients with particularly severe or disturbing NPS and those suffering
from aberrant motor behavior are often more visible on the wards as
they tend to require more medical and nursing resources. However,
as our analysis has shown, the majority of patients was physically inac-
tive and sedentary, and we assume from our clinical experience, that
sedentary patients often go more or less unnoticed in acute dementia
care. From the clinical expertise of the authors, this phenomenon can
very often be translated to nursing‐home or home‐care settings.Furthermore, this study confirms the findings of Eggermont and
Scherder,34 who found that nursing home residents suffering from
dementia were classified as ambulatory, were nevertheless sedentary
for almost the whole day. This physical inactivity may be directly
linked to the development and exacerbation of psychopathological
symptoms.10,11
The availability of objective, quantitative data on dementia
patients' physical inactivity could be used to prompt a change in care
strategy and a new focus on physical activity in acute dementia care.
There is increasing evidence that exercise programs have a beneficial
effect on patients' ability to perform activities of daily living as well
as decreasing the caregiver burden in dementia care.35 Furthermore,
structured physical exercise interventions have been shown to be an
effective treatment for NPS in dementia.7,8
It is important to note that our analyses did not include all medi-
cations that could influence patients' physical activity, for example
we did not assess use of antidepressants and antidementics. Because
we wanted to analyze synchronized activity and medication data, only
sensor data from the first complete 24‐hour period from midnight
were used in the analyses presented here. Recording activity over a
longer period would allow a more robust analysis and interpretation
of patients' physical activity. Because we excluded outliers our analy-
sis does not cover the full spectrum of physical activity in dementia
patients, eg, a patient who showed a wandering phenomenon and
thus took more than 40 000 steps per day had to be excluded.
These limitations should be taken into account when interpreting
the results. As objective assessments of dementia patients' physical
activity become more widespread, we may see an increase in the
emphasis on motor behavior. The availability of objective measures
6 FLEINER ET AL.of physical activity makes it possible to design and evaluate individual-
ized exercise interventions that might help to reduce NPS and increase
patients, caregivers', and medical professionals' quality of life.
In summary, physical inactivity in patients suffering from demen-
tia seems to be a feature of the psychopathology of the disease rather
than an effect of antipsychotic or benzodiazepine medication. Demen-
tia care should pay more attention to prevent physical inactivity in
patients. There is an urgent need for effective non‐pharmacological
treatments for NPS as use of antipsychotics and benzodiazepines to
treat NPS in patients suffering from dementia has been linked to seri-
ous adverse effects.36,37
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